Is breast conserving therapy better than mastectomy? Surgeons must speak out.


Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356

Informations de publication

Date de publication:
08 2020
Historique:
received: 06 04 2020
revised: 01 05 2020
accepted: 08 05 2020
pubmed: 23 5 2020
medline: 1 1 2021
entrez: 23 5 2020
Statut: ppublish

Résumé

Several population-based studies suggest that breast conserving surgery followed by radiotherapy (BCT) may provide longer overall survival than mastectomy. Better locoregional control after BCT due to improvements of preoperative imaging, oncoplastic surgery and radiotherapy, as well as the recent trend towards surgical de-escalation may be involved. Alternatively, modern radiotherapy may have such an improved benefit/risk ratio that its survival advantage now stands out more clearly. However, since the therapeutic equivalence of BCT and mastectomy was demonstrated by several randomised trials, this information cannot be disregarded, nor radiotherapy should be used to compensate for inadequate surgery. Both BCT and mastectomy are likely here to stay as clinical presentation of breast cancer is highly variable, and women desires may transcend a rational balance of pros and cons between the two surgical approaches. Our duty as surgeons is to lead the multidisciplinary board and accompany the patients along this difficult decision-making process.

Identifiants

pubmed: 32439264
pii: S0748-7983(20)30458-3
doi: 10.1016/j.ejso.2020.05.005
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1551-1553

Informations de copyright

Copyright © 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest None.

Auteurs

Riccardo Ponzone (R)

Gynaecological Oncology, Candiolo Cancer Institute, FPO - IRCCS, Italy. Electronic address: riccardo.ponzone@ircc.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH